HC Wainwright Issues Pessimistic Forecast for ACTU Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – Equities research analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for Actuate Therapeutics in a report issued on Monday, May 18th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.20) for the quarter, down from their previous estimate of ($0.17). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Actuate Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Actuate Therapeutics’ Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.84) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.71) EPS, FY2028 earnings at ($0.75) EPS and FY2029 earnings at ($0.07) EPS.

Several other brokerages have also commented on ACTU. Weiss Ratings restated a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Friday, March 27th. Wall Street Zen upgraded Actuate Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $17.50.

Actuate Therapeutics Trading Down 1.2%

Shares of Actuate Therapeutics stock opened at $2.40 on Wednesday. The firm has a market cap of $57.43 million, a P/E ratio of -2.47 and a beta of 0.92. Actuate Therapeutics has a 12 month low of $1.58 and a 12 month high of $11.99. The stock’s fifty day moving average price is $2.54 and its 200-day moving average price is $4.59.

Actuate Therapeutics (NASDAQ:ACTU) last released its earnings results on Thursday, May 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01).

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ACTU. ABS Direct Equity Fund LLC acquired a new position in Actuate Therapeutics in the fourth quarter valued at approximately $40,000. Deutsche Bank AG grew its holdings in Actuate Therapeutics by 640.0% in the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock valued at $57,000 after buying an additional 8,051 shares in the last quarter. Barclays PLC grew its holdings in Actuate Therapeutics by 68.6% in the 4th quarter. Barclays PLC now owns 14,946 shares of the company’s stock valued at $91,000 after buying an additional 6,081 shares in the last quarter. Bank of America Corp DE grew its holdings in Actuate Therapeutics by 61,068.0% in the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after buying an additional 15,267 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Actuate Therapeutics during the 4th quarter worth $102,000.

Key Headlines Impacting Actuate Therapeutics

Here are the key news stories impacting Actuate Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Actuate Therapeutics and maintained a $15.00 price target, implying substantial upside from the current share price. Benzinga article
• Neutral Sentiment: The analyst still expects Actuate to post losses over the next several years, with projected EPS of $(0.84) in FY2026, $(0.71) in FY2027, and $(0.75) in FY2028, suggesting the company remains in an early development phase.
• Negative Sentiment: HC Wainwright lowered multiple earnings forecasts, including Q2 2026 to $(0.20) from $(0.17), Q3 2026 to $(0.21) from $(0.18), Q4 2026 to $(0.23) from $(0.19), and FY2029 to $(0.07) from $0.04, signaling a more cautious outlook.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.